WHO ICTRP trial
A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant…
ChiCTR2300073056 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2300073056 |
|---|---|
| Public title | A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C) in Booster Vaccination in Healthy Population 18 Years Old of Age and Above |
| Scientific title | A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination |
| Primary sponsor | Jiangsu Center for Disease Control and Prevention (Jiangsu Institute of Public Health) |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | COVID-19 |
| Interventions | Experimental group:Recombinant Bivalent COVID-19 (XBB variant + prototype strain) Protein Vaccine (Sf9 cells)(WSK-V101C);Active Comparator: Control group:Recombinant COVID-19 vaccine (Sf9 cells)(WSK-V101) |
| Registration date | Jun 30, 2023 |
| Target size | Experimental group:3000;Active Comparator: Control group:100 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: